All News
´The health care professionals ànd caregivers also need to be well in order to deliver care for patients’ Andrea Marques speaking at the self-management session at #EULAR2024 @RheumNow https://t.co/BrEHPTbbti
Dr. Antoni Chan synovialjoints ( View Tweet)
Autoantibody measures in 5 scandinavian cohorts 6900+ RA pts
Four cit-peptides w/ high frequency
Cit Fibb36-52 (51%) Cit Fibb60-74-Cit3 (59%) Cit Fil307-324 (54%) Cit Vim60-75-Cit1 (63%)
Capture 97% of IgG CCP2+ & 22% IgG CCP2-
42% of all pts + IgG anti-Carb or Acet peptides… https://t.co/yYr6AzgipM https://t.co/6dP6Sgi3yB
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2024
@AilsaBosworth1 highlights the programmes available for pts diagnosed with #RA via the @NRAS_UK platform
SMILE-RA and RightStart are great resources for self-management, can highly recommend to all clinicians!
@RheumNow https://t.co/SgAMKkcycE
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Just some of the barriers to supporting patients in self-management.
Important to note the array of factors at play, some easier to address than others but all should be acknowledged to tailor individual self-management guidance.
@RheumNow @ElenaNikiUK #EULAR2024 https://t.co/GJM35l275V
Mrinalini Dey DrMiniDey ( View Tweet)
« Glucocorticoids are such old drugs and we still use them so much » says Josef Smolen
Summary slide from « 75th anniversary of GCd, what have we learnt? »
@RheumNow #EULAR2024 https://t.co/XSRt44zupw
Aurelie Najm AurelieRheumo ( View Tweet)
From the Be-GIANT cohort, 44.3% of patients met the definition of early axSpA (<2 year symptom). The early axSpA group had younger age and lower frequency of radiographic sacroiliitis. Baseline characteristics and disease activity scores at baseline were similar. Physicians… https://t.co/6stDw8sHiI https://t.co/fjINAc4mw3
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024
@ElenaNikiUK highlights the need to treat the patient not the disease, being cognisant of interacting factors incl #comorbidities
(Don’t think I’ll ever quite get used to seeing my work being referenced on the big screen!)
@RheumNow https://t.co/0tFUR03q8c
Mrinalini Dey DrMiniDey ( View Tweet)
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
FINDINGS ON MRI OF THE SACROILIAC JOINTS 7 YEARS AFTER PREGNANCY IN WOMEN WITH AND WITHOUT POSTPARTUM BUTTOCK/PELVIC PAIN - source of misdiagnosis but not a cause of progressive lesions @RheumNow #EULAR2024 https://t.co/aEvlkMZtQw
Peter Nash drpnash ( View Tweet)
OP0238-HPR: effectiveness of digital patient education programme for RA self-management
Intervention led to improved self-efficacy, w minor improved RA knowledge, #HealthLiteracy & #QoL
➡️such interventions may improve self-management & lower health costs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Some of the great questions in ICI-induced irAE pathophysiology, from the great Andy Cope @KingsCollegeLon
#EULAR2024 @RheumNow https://t.co/aHDqnvhboo
David Liew drdavidliew ( View Tweet)
🙏🏻I am so grateful for @RheumNow's coverage of our research about radiomics in AxSpA
⭐️I believe radiomics has potential and hope it will become a thing in Rheumatology
👇🏻Here is my interview with @bella_mehta about POS 0236 which I presented at #EULAR2024
https://t.co/yvD9yCIzQ8
Vincenzo Venerito vincevenerito ( View Tweet)
DEFINING OVERALL AND SEX-SPECIFIC BASDAI CUT-OFFS FOR DISEASE ACTIVITY STATES IN AXIAL SPONDYLARTHRITIS – RESULTS FROM THE EUROSPA COLLABORATION - more data to stratify for gender at baseline all future AxSpA trials @RheumNow #EULAR2024 https://t.co/nQwCDOxN8R
Peter Nash drpnash ( View Tweet)
#EULAR2024 #scleroderma #recommend’ns @eular_org
#lung #ILD
Divide in to
#prevention vs #Rx
#Immune #suppressive #Rx vs
#antifibrotic
My thoughts -?other Rx as ⬆️MR
Likely all effective early #Rx of skin
Improve Risk of
#progression▶️ILD
@EUSTAR_org @RheumNow https://t.co/4wJyeSEHv3
Links:
Janet Pope Janetbirdope ( View Tweet)
EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY - IL17 effective & safe in JIA @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Izokibep Ph2b/3 RCT PsA 340+
Primary endpoint ACR50 wk 16
IZO 160 mg Q2W 43%
IZO 160 mg QW 40%
PBO 15%
Effect early as wk 4
PASI100
IZO Q2W 47%
IZO QW 51%
PBO 12%
Safety profile similar to IL-17i
@RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX
Aurelie Najm AurelieRheumo ( View Tweet)
ReMonit RCT 240+ axSPA pts
Remote Monitoring & Patient-initiated Care NON INFERIOR Usual care for ASDAS <2.1 over 18mo
No diff between Patient-initiated Care & Remote Monitoring
No diff in disease activity & function
>90% satisfaction in all arms
#EULAR2024 @RheumNow LB0004 https://t.co/mLTS5fLXFN
Aurelie Najm AurelieRheumo ( View Tweet)
This is critical.
If we're going to try and treat pre-RA, it's all about picking the right patient:
- avoid exposing future non-responders to harm
- modify the course of disease in those who will benefit
Fantastic that @eular_org are addressing this need.
#EULAR2024 @RheumNow https://t.co/9pF33eLbuZ
David Liew drdavidliew ( View Tweet)
Scleroderma: the present, and the future.
#EULAR2024 @RheumNow https://t.co/v5vxfmM4i3
David Liew drdavidliew ( View Tweet)
Open-label extension of BE MOBILE 2 Ph3 Bimekizumab in r-axSpA
200 pts w/ 2yr radiographic outcome
85.3% non progressors (mSASSS CfB ≤0.5) 92.1% (mSASSS CfB <2)
83.1% had existing structural damage (mSASSS ≥2) at BL
#EULAR2024 @RheumNow Abst LBA0003 https://t.co/DQeiXHDnSF
Aurelie Najm AurelieRheumo ( View Tweet)